Patent Expirations as of 9/14/2012

Patent Expirations 9/14/12
Abilify 4/20/15 Levitra 10/31/18
Aciphex 5/8/13 Loestrin 24 FE 1/22/14**
Actonel 6/10/14 Loestrin 24 FE 1/22/14**
Adenoscan 9/2012** Lunesta 5/31/14#
Aggrenox 7/1/15** Lyrica 12/30/18
Androgel 2015** Maxalt 12/29/12#
Avodart 11/20/15 Meridia 1/25/13
Azilect 2/7/17 Miacalcin 3/31/15
Benicar 10/25/16 Micardis 1/7/14
Bystolic 6/17/15 Mucinex 7/1/12
Celebrex 5/30/14 Namenda 1/11/15**
Concerta 7/14/13** Nasonex anytime
Copaxone 5/24/14 Nexium 5/27/14
Crestor 7/8/2016 Ortho Tri-Cyclen Lo 12/31/15**
Cymbalta 12/11/13# Patanol 12/6/15
Detrol LA 1/1/14** Strattera 5/26/17
Dexilant 12/15/20# Vesicare 10/2018
Diovan 9/21/12 (delayed due to labeling issues) Viagra 10/2019** Subject to appeal
Evista 30-month stay ends 11/3/12 Vytorin 4/25/17
Femcon FE 1/1/13** Vyvanse 30-month stay ends 8/23/14
All information is believed to accurate and reliable, but is subject to correction and change Zetia 4/25/2017
www.capital-drug.com
# Indicates Pediatric extension granted
** Indicates License Agreement or Patent Litigation Resolution
This entry was posted in Industry Updates. Bookmark the permalink.

Comments are closed.